Association between serum adiponectin, and pathological stage and grade in men undergoing radical prostatectomy

Stephen J. Freedland, Lori J Sokoll, Elizabeth A Platz, Leslie A. Mangold, Debra J. Bruzek, Phaedre Mohr, Sindy K. Yiu, Alan Wayne Partin

Research output: Contribution to journalArticle

Abstract

Purpose: Adiponectin is a polypeptide hormone produced by adipocytes that has antiangiogenic properties. Circulating adiponectin is lower in obese men. Obesity has been associated with advanced stage and a higher risk of biochemical progression following radical prostatectomy (RP) in several series. We examined whether serum adiponectin is associated with advanced disease stage at RP. Materials and Methods: Adiponectin was measured by enzyme-linked immunosorbent assay in the preoperative serum of 236 men treated with RP between 1998 and 1999. The odds ratio (OR) of advanced stage (pT3a or greater) and high grade disease (pathological Gleason sum 7 or greater) associated with quartiles of adiponectin were estimated using multivariate logistic regression models. Results: Serum adiponectin weakly correlated inversely with body mass index (Spearman r = -0.22, p = 0.01). Serum adiponectin was not associated with cancer stage or grade. However, in normal weight men adiponectin was positively associated with high stage disease (OR 1.14, 95% CI 1.02 to 1.29, p = 0.03), although there was no statistically significant association with high grade disease (OR 1.05, 95% CI 0.94 to 1.18, p = 0.38). In overweight and obese men adiponectin was inversely associated with high grade disease (OR 0.94, 95% CI 0.87 to 1.01, p = 0.09), although there was no statistically significant association with high stage disease (OR 0.97, 95% CI 0.91 to 1.04, p = 0.43). Further adjustments for body mass index had little impact on any ORs. Conclusions: These data provide evidence to suggest that adiponectin may be related to prostate cancer aggressiveness, although the direction of the associations may depend on the extent of adiposity and on cancer grade.

Original languageEnglish (US)
Pages (from-to)1266-1270
Number of pages5
JournalJournal of Urology
Volume174
Issue number4 I
DOIs
StatePublished - Oct 2005
Externally publishedYes

Fingerprint

Adiponectin
Prostatectomy
Serum
Odds Ratio
Body Mass Index
Logistic Models
Peptide Hormones
Adiposity
Adipocytes
Neoplasms
Obesity
Enzyme-Linked Immunosorbent Assay
Weights and Measures

Keywords

  • Adiponectin
  • Obesity
  • Prostate
  • Prostatectomy
  • Prostatic neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Association between serum adiponectin, and pathological stage and grade in men undergoing radical prostatectomy. / Freedland, Stephen J.; Sokoll, Lori J; Platz, Elizabeth A; Mangold, Leslie A.; Bruzek, Debra J.; Mohr, Phaedre; Yiu, Sindy K.; Partin, Alan Wayne.

In: Journal of Urology, Vol. 174, No. 4 I, 10.2005, p. 1266-1270.

Research output: Contribution to journalArticle

Freedland, Stephen J. ; Sokoll, Lori J ; Platz, Elizabeth A ; Mangold, Leslie A. ; Bruzek, Debra J. ; Mohr, Phaedre ; Yiu, Sindy K. ; Partin, Alan Wayne. / Association between serum adiponectin, and pathological stage and grade in men undergoing radical prostatectomy. In: Journal of Urology. 2005 ; Vol. 174, No. 4 I. pp. 1266-1270.
@article{fc3481ca708f4421add378404e17e208,
title = "Association between serum adiponectin, and pathological stage and grade in men undergoing radical prostatectomy",
abstract = "Purpose: Adiponectin is a polypeptide hormone produced by adipocytes that has antiangiogenic properties. Circulating adiponectin is lower in obese men. Obesity has been associated with advanced stage and a higher risk of biochemical progression following radical prostatectomy (RP) in several series. We examined whether serum adiponectin is associated with advanced disease stage at RP. Materials and Methods: Adiponectin was measured by enzyme-linked immunosorbent assay in the preoperative serum of 236 men treated with RP between 1998 and 1999. The odds ratio (OR) of advanced stage (pT3a or greater) and high grade disease (pathological Gleason sum 7 or greater) associated with quartiles of adiponectin were estimated using multivariate logistic regression models. Results: Serum adiponectin weakly correlated inversely with body mass index (Spearman r = -0.22, p = 0.01). Serum adiponectin was not associated with cancer stage or grade. However, in normal weight men adiponectin was positively associated with high stage disease (OR 1.14, 95{\%} CI 1.02 to 1.29, p = 0.03), although there was no statistically significant association with high grade disease (OR 1.05, 95{\%} CI 0.94 to 1.18, p = 0.38). In overweight and obese men adiponectin was inversely associated with high grade disease (OR 0.94, 95{\%} CI 0.87 to 1.01, p = 0.09), although there was no statistically significant association with high stage disease (OR 0.97, 95{\%} CI 0.91 to 1.04, p = 0.43). Further adjustments for body mass index had little impact on any ORs. Conclusions: These data provide evidence to suggest that adiponectin may be related to prostate cancer aggressiveness, although the direction of the associations may depend on the extent of adiposity and on cancer grade.",
keywords = "Adiponectin, Obesity, Prostate, Prostatectomy, Prostatic neoplasms",
author = "Freedland, {Stephen J.} and Sokoll, {Lori J} and Platz, {Elizabeth A} and Mangold, {Leslie A.} and Bruzek, {Debra J.} and Phaedre Mohr and Yiu, {Sindy K.} and Partin, {Alan Wayne}",
year = "2005",
month = "10",
doi = "10.1097/01.ju.0000173093.89897.97",
language = "English (US)",
volume = "174",
pages = "1266--1270",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "4 I",

}

TY - JOUR

T1 - Association between serum adiponectin, and pathological stage and grade in men undergoing radical prostatectomy

AU - Freedland, Stephen J.

AU - Sokoll, Lori J

AU - Platz, Elizabeth A

AU - Mangold, Leslie A.

AU - Bruzek, Debra J.

AU - Mohr, Phaedre

AU - Yiu, Sindy K.

AU - Partin, Alan Wayne

PY - 2005/10

Y1 - 2005/10

N2 - Purpose: Adiponectin is a polypeptide hormone produced by adipocytes that has antiangiogenic properties. Circulating adiponectin is lower in obese men. Obesity has been associated with advanced stage and a higher risk of biochemical progression following radical prostatectomy (RP) in several series. We examined whether serum adiponectin is associated with advanced disease stage at RP. Materials and Methods: Adiponectin was measured by enzyme-linked immunosorbent assay in the preoperative serum of 236 men treated with RP between 1998 and 1999. The odds ratio (OR) of advanced stage (pT3a or greater) and high grade disease (pathological Gleason sum 7 or greater) associated with quartiles of adiponectin were estimated using multivariate logistic regression models. Results: Serum adiponectin weakly correlated inversely with body mass index (Spearman r = -0.22, p = 0.01). Serum adiponectin was not associated with cancer stage or grade. However, in normal weight men adiponectin was positively associated with high stage disease (OR 1.14, 95% CI 1.02 to 1.29, p = 0.03), although there was no statistically significant association with high grade disease (OR 1.05, 95% CI 0.94 to 1.18, p = 0.38). In overweight and obese men adiponectin was inversely associated with high grade disease (OR 0.94, 95% CI 0.87 to 1.01, p = 0.09), although there was no statistically significant association with high stage disease (OR 0.97, 95% CI 0.91 to 1.04, p = 0.43). Further adjustments for body mass index had little impact on any ORs. Conclusions: These data provide evidence to suggest that adiponectin may be related to prostate cancer aggressiveness, although the direction of the associations may depend on the extent of adiposity and on cancer grade.

AB - Purpose: Adiponectin is a polypeptide hormone produced by adipocytes that has antiangiogenic properties. Circulating adiponectin is lower in obese men. Obesity has been associated with advanced stage and a higher risk of biochemical progression following radical prostatectomy (RP) in several series. We examined whether serum adiponectin is associated with advanced disease stage at RP. Materials and Methods: Adiponectin was measured by enzyme-linked immunosorbent assay in the preoperative serum of 236 men treated with RP between 1998 and 1999. The odds ratio (OR) of advanced stage (pT3a or greater) and high grade disease (pathological Gleason sum 7 or greater) associated with quartiles of adiponectin were estimated using multivariate logistic regression models. Results: Serum adiponectin weakly correlated inversely with body mass index (Spearman r = -0.22, p = 0.01). Serum adiponectin was not associated with cancer stage or grade. However, in normal weight men adiponectin was positively associated with high stage disease (OR 1.14, 95% CI 1.02 to 1.29, p = 0.03), although there was no statistically significant association with high grade disease (OR 1.05, 95% CI 0.94 to 1.18, p = 0.38). In overweight and obese men adiponectin was inversely associated with high grade disease (OR 0.94, 95% CI 0.87 to 1.01, p = 0.09), although there was no statistically significant association with high stage disease (OR 0.97, 95% CI 0.91 to 1.04, p = 0.43). Further adjustments for body mass index had little impact on any ORs. Conclusions: These data provide evidence to suggest that adiponectin may be related to prostate cancer aggressiveness, although the direction of the associations may depend on the extent of adiposity and on cancer grade.

KW - Adiponectin

KW - Obesity

KW - Prostate

KW - Prostatectomy

KW - Prostatic neoplasms

UR - http://www.scopus.com/inward/record.url?scp=24944465001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24944465001&partnerID=8YFLogxK

U2 - 10.1097/01.ju.0000173093.89897.97

DO - 10.1097/01.ju.0000173093.89897.97

M3 - Article

C2 - 16145390

AN - SCOPUS:24944465001

VL - 174

SP - 1266

EP - 1270

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 4 I

ER -